CANCER OF SPECIFIED SEVERITY. I. A malignant tumor characterized by the uncontrolled growth and spread of malignant cells with invasion and destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy. The term cancer includes leukemia, lymphoma and sarcoma.
II. The following are excluded –
i. All tumors which are histologically described as carcinoma in situ, benign, pre-malignant, borderline malignant, low malignant potential, neoplasm of unknown behavior, or non-invasive, including but not limited to: Carcinoma in situ of breasts, Cervical dysplasia CIN-1, CIN - 2 and CIN-3.
ii. Any non-melanoma skin carcinoma unless there is evidence of metastases to lymph nodes or beyond;
iii. Malignant melanoma that has not caused invasion beyond the epidermis;
iv. All tumors of the prostate unless histologically classified as having a Xxxxxxx score greater than 6 or having progressed to at least clinical TNM classification T2N0M0
v. All Thyroid cancers histologically classified as T1N0M0 (TNM Classification) or below;
vi. Chronic lymphocytic leukaemia less than RAI stage 3
vii. Non-invasive papillary cancer of the bladder histologically described as TaN0M0 or of a lesser classification,
viii. All Gastro-Intestinal Stromal Tumors histologically classified as T1N0M0 (TNM Classification) or below and with mitotic count of less than or equal to 5/50 HPFs;
ix. All tumors in the presence of HIV infection.
CANCER OF SPECIFIED SEVERITY i. Details of the treatment received by the Insured Person from the inception of the ailment.
ii. Letter from treating consultant stating presenting complaints with duration and the past medical history.
iii. Histopathology / Cytology / FNAC / Biopsy / Immuno-histochemistry reports.
iv. X-Ray / CT scan / MRI scan / USG / Radioisotope / Bone scan Reports.
CANCER OF SPECIFIED SEVERITY. (i) A malignant tumour characterized by the uncontrolled growth & spread of malignant cells with invasion & destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy & confirmed by a pathologist. The term cancer includes leukemia, lymphoma and sarcoma.
(ii) The following are excluded -
i. Tumours showing the malignant changes of carcinoma in situ & tumours which are histologically described as premalignant or non invasive, including but not limited to: Carcinoma in situ of breasts, Cervical dysplasia CIN-1, CIN -2 & CIN-3.
ii. Any skin cancer other than invasive malignant melanoma
iii. All tumours of the prostate unless histologically classified as having a Xxxxxxx score greater than 6 or having progressed to at least clinical TNM classification T2N0M0
iv. Papillary micro - carcinoma of the thyroid less than 1 cm in diameter v. Chronic lymphocyctic leukaemia less than RAI stage 3
CANCER OF SPECIFIED SEVERITY. A malignant tumor characterised by the uncontrolled growth & spread of malignant cells with invasion & destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy & confirmed by a pathologist. The term cancer includes leukemia, lymphoma and sarcoma:
a. Tumors showing the malignant changes of carcinoma in situ & tumors which are histologically described as premalignant or non invasive, including but not limited to: Carcinoma in situ of breasts, Cervical dysplasia CIN-1, CIN -2 & CIN-3.
b. Any skin cancer other than invasive malignant melanoma.
c. All tumors of the prostate unless histologically classified as having a Xxxxxxx score greater than 6 or having progressed to at least clinical TNM classification T2N0M0...
d. Papillary micro - carcinoma of the thyroid less than 1 cm in diameter e. Chronic lymphocytic leukemia less than RAI stage 3
CANCER OF SPECIFIED SEVERITY. I. A malignant tumor characterized by the uncontrolled growth and spread of malignant cells with invasion and destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy. The term cancer includes leukemia, lymphoma and sarcoma.
II. The following are excluded –
I. All tumors which are histologically described as carcinoma in situ, benign, pre-malignant, borderline malignant, low malignant potential, neoplasm of unknown behavior, or non-invasive, including but not limited to: Carcinoma in situ of breasts, Cervical dysplasia CIN-1, CIN -
CANCER OF SPECIFIED SEVERITY. A malignant tumor characterised by the uncontrolled growth & spread of malignant cells with invasion & destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy & confirmed by a pathologist. The term cancer includes leukemia, lymphoma and sarcoma:
a. Tumors showing the malignant changes of carcinoma in situ & tumors which are histologically described as premalignant or non invasive, including but not limited to: Carcinoma in situ of breasts, Cervical dysplasia CIN-1, CIN -2 & CIN-3.
b. Any skin cancer other than invasive malignant melanoma.
CANCER OF SPECIFIED SEVERITY. A malignant tumour characterised by the uncontrolled growth and spread of malignant cells with invasion and destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy. The term cancer includes leukaemia, lymphoma and sarcoma. The following are excluded:
CANCER OF SPECIFIED SEVERITY. I. A malignant tumor characterized by the uncontrolled growth and spread of malignant cells with invasion and destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy. The term cancer includes leukemia, lymphoma and sarcoma.
II. The following are excluded –
i. All tumors which are histologically described as carcinoma in situ, benign, pre- malignant, borderline malignant, low malignant potential, neoplasm of unknown behaviour, or non-invasive, including but not limited to: Carcinoma in situ of breasts, Cervical dysplasia CIN-1, CIN -2 and CIN-3. Insurance is the subject ma�er of solicita�on. Max Bupa Health Insurance Company Limited (IRDA Registra�on Number 145), ‘Max’, ‘Max Logo’, ‘Bupa’ and ‘HEARTBEAT’ logo are trademarks of their respec�ve owners and are being used by Max Bupa Health Insurance Company Limited under license. Registered office:- Xxx Xxxxx, 0 Xx. Xxx Xxxx, Okhla, New Delhi-110020, Corporate Office: B-1/I-2, Mohan Xxxxxxx�xx Xxxxxxxxxx Xxxxxx, Xxxxxxx Xxxx, Xxx Xxxxx - 000000; Fax: +00 00 00000000; Toll free: 1860-3010-3333; xxx.xxxxxxx.xxx. CIN: U66000DL2008PLC182918. Product UIN- IRDAI/HLT/MBHI/P-H(G)/V.I/53/2016-17
ii. Any non-melanoma skin carcinoma unless there is evidence of metastases to lymph nodes or beyond;
iii. Malignant melanoma that has not caused invasion beyond the epidermis;
iv. All tumors of the prostate unless histologically classified as having a Xxxxxxx score greater than 6 or having progressed to at least clinical TNM classification T2N0M0
v. All Thyroid cancers histologically classified as T1N0M0 (TNM Classification) or below;
vi. Chronic lymphocytic leukaemia less than RAI stage 3
vii. Non-invasive papillary cancer of the bladder histologically described as TaN0M0 or of a lesser classification,
viii. All Gastro-Intestinal Stromal Tumors histologically classified as T1N0M0 (TNM Classification) or be low and with mitotic count of less than or equal to 5/50 HPFs;
ix. All tumors in the presence of HIV infection.
CANCER OF SPECIFIED SEVERITY. (i) A malignant tumor characterized by the uncontrolled growth & spread of malignant cells with invasion & destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy & confirmed by a pathologist. The term cancer includes leukemia, Lymphoma and Sarcoma.
(ii) The following are excluded -
(a) Tumours showing the malignant changes of Carcinoma in situ & Tumours which are histologically described as premalignant or non invasive, including but not limited to: Carcinoma in situ of breasts, Cervical Dysplasia CIN-1, CIN-2 & CIN-3.
(b) Any skin cancer other than invasive Malignant Melanoma
(c) All Tumours of the prostate unless histologically classified as having a Xxxxxxx score greater than 6 or having progress to at least clinical TNM classification T2N0M0
(d) Papillary Micro - Carcinoma of the Thyroid less than 1 cm in diameter (e) Chronic Lymphocyctic Leukaemia less than RAI stage 3
CANCER OF SPECIFIED SEVERITY. (i) A malignant tumour characterized by the uncontrolled growth & spread of malignant cells with invasion & destruction of normal tissues. This diagnosis must be supported by histological evidence of malignancy & confirmed by a pathologist. The term cancer includes leukemia, lymphoma and sarcoma.
(ii) The following are excluded -
i. Tumours showing the malignant changes of carcinoma in situ & tumours which are histologically described as premalignant or non invasive, including but not limited to: Carcinoma in situ of breasts, Cervical dysplasia CIN-1, CIN -2 & CIN-3.
ii. Any skin cancer other than invasive malignant melanoma
iii. All tumours of the prostate unless histologically classified as having a Xxxxxxx score greater than 6 Page 3; Kotak Mahindra General Insurance Company Ltd.; Kotak Secure Shield UIN; IRDAI/HLT/KMGI/P-H/V.I/06/2016-17; Policy Wording or having progressed to at least clinical TNM classification T2N0M0
iv. Papillary micro - carcinoma of the thyroid less than 1 cm in diameter v. Chronic lymphocyctic leukaemia less than RAI stage 3
